ARENA PHARMACEUTICALS INC's ticker is ARNA and the CUSIP is 040047607. A total of 243 filers reported holding ARENA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $490,000 | -33.2% | 5,269 | -57.2% | 0.01% | -44.4% |
| Q3 2021 | $733,000 | +20.8% | 12,315 | +40.8% | 0.01% | +12.5% |
| Q1 2021 | $607,000 | +274.7% | 8,749 | +314.6% | 0.01% | +300.0% |
| Q4 2020 | $162,000 | +575.0% | 2,110 | +569.8% | 0.00% | – |
| Q3 2020 | $24,000 | -56.4% | 315 | -63.8% | 0.00% | -100.0% |
| Q2 2020 | $55,000 | +129.2% | 870 | +52.6% | 0.00% | 0.0% |
| Q1 2020 | $24,000 | -95.3% | 570 | -94.9% | 0.00% | -88.9% |
| Q4 2019 | $507,000 | +4970.0% | 11,165 | +5267.8% | 0.01% | – |
| Q3 2019 | $10,000 | +66.7% | 208 | +108.0% | 0.00% | – |
| Q2 2019 | $6,000 | -96.2% | 100 | -97.5% | 0.00% | -100.0% |
| Q4 2018 | $157,000 | +49.5% | 4,022 | +76.2% | 0.01% | +16.7% |
| Q3 2018 | $105,000 | -87.9% | 2,283 | -88.5% | 0.01% | -86.4% |
| Q2 2018 | $868,000 | +823.4% | 19,900 | +622.8% | 0.04% | +780.0% |
| Q4 2017 | $94,000 | -46.0% | 2,753 | -59.5% | 0.01% | -50.0% |
| Q3 2017 | $174,000 | – | 6,805 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 163,133 | $7,467,000 | 4.14% |
| PFM Health Sciences, LP | 2,271,536 | $103,968,000 | 3.07% |
| Partner Investment Management, L.P. | 28,877 | $1,322,000 | 2.26% |
| Atika Capital Management LLC | 181,000 | $8,284,000 | 1.74% |
| DAFNA Capital Management LLC | 93,942 | $4,300,000 | 1.62% |
| Asymmetry Capital Management, L.P. | 16,272 | $745,000 | 1.60% |
| First Light Asset Management, LLC | 190,838 | $8,735,000 | 1.32% |
| Perceptive Advisors | 953,129 | $43,624,000 | 1.18% |
| Rhenman & Partners Asset Management AB | 155,000 | $7,094,000 | 0.89% |
| Opus Point Partners Management, LLC | 9,770 | $447,000 | 0.81% |